Overview

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).
Phase:
Phase 2
Details
Lead Sponsor:
Forest Laboratories
Treatments:
Citalopram
Dexetimide
Fluoxetine
Levomilnacipran
Milnacipran
Paroxetine
Sertraline